

39. (Currently amended) The method of claim 37 ~~38~~, wherein said disease, ~~or condition or disorder~~ is ~~a non-autoimmune~~ transplant rejection or graft-versus-host disease.

40. (Currently amended) The method of claim 37 wherein said disease, ~~or condition or disorder~~ is an allergic condition.

41. (Previously added) The method of claim 40 wherein said allergic condition is asthma.

42. (Currently amended) The method of claim 37 wherein said chimeric anti-CD4 antibody has a human antibody gamma 4 constant ~~domain~~ region.

43. (Currently amended) The method of claim 37 wherein said anti-CD4 antibody has a human antibody gamma 1 constant ~~domain~~ region.

44. (Currently amended) The method of claim 42 wherein said gamma 4 constant region ~~domain has the amino acids at position 229 and 236 in the constant region respectively changed from a serine to a proline and a leucine to glutamic acid~~ comprises at least one mutation selected from the group consisting of:

substitution of glutamic acid in place of leucine at position 248 (Kabat numbering);  
and

substitution of proline in place of serine at position 241 (Kabat numbering).

45. (Currently amended) The method of claim 37 wherein said Old World Monkey ~~variable~~ heavy and light chain variable regions ~~are~~ have polypeptide sequences encoded by the DNA sequences ~~having in~~ SEQ ID NO.: 3 and SEQ ID NO.: 1 respectively.

46. (Currently amended) The method of claim 37 ~~38~~, wherein said disease, ~~or condition or disorder~~ is lymphoma.

47. (Currently amended) The method of claim 37 wherein said disease, ~~or condition or disorder~~ is an autoimmune or chronic inflammatory disease, condition or disorder.

48. (Currently amended) The method of claim 37 ~~47~~, wherein said autoimmune or chronic inflammatory disease, -or condition or disorder is selected from the group consisting of Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious

anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, multiple sclerosis, male infertility, pemphigus vulgaris, pemphigoid, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, inflammatory bowel disease syndrome, Sjögren's syndrome, psoriasis, rheumatoid arthritis, dermatomyositis, scleroderma, mixed tissue connective disease, discoid lupus erythematosus, systemic vasculitis, and systemic lupus erythematosus (SLE).

**New claims:**

49. (New) The method of claim 48, wherein the autoimmune or chronic inflammatory disease, condition or disorder is selected from the group consisting of rheumatoid arthritis, psoriasis, type I-diabetes mellitus, cirrhosis, inflammatory bowel disease, SLE, and multiple sclerosis.

50. (New) The method of claim 37, wherein the chimeric anti-CD4 antibody comprises:

a heavy chain having a polypeptide sequence selected from the group consisting of the gamma 4 heavy chain polypeptide sequence in SEQ ID NO:7, the gamma 4 (E) heavy chain polypeptide sequence in SEQ ID NO:9; and the gamma 4 (PE) heavy chain polypeptide sequence in SEQ ID NO:11; and

a light chain having the variable region polypeptide sequence in SEQ ID NO:1 and a constant region polypeptide sequence of a human kappa or lambda light chain.

51. (New) The method of claim 50, wherein the chimeric anti-CD4 antibody comprises a heavy chain having the gamma 4 heavy chain polypeptide sequence in SEQ ID NO:7.

52. (New) The method of claim 50, wherein the chimeric anti-CD4 antibody comprises a heavy chain having the gamma 4 (E) heavy chain polypeptide sequence in SEQ ID NO:9.